Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Nov 16;13:1073543. doi: 10.3389/fphar.2022.1073543

Corrigendum: Polydeoxyribonucleotide, an adenosine-A2A receptor agonist, preserves blood testis barrier from cadmium-induced injury

Francesco Squadrito 1, Antonio Micali 2, Mariagrazia Rinaldi 1, Natasha Irrera 1, Herbert Marini 1, Domenico Puzzolo 2, Antonina Pisani 2, Cesare Lorenzini 3, Andrea Valenti 1, Rosaria Laurà 4, Antonino Germanà 4, Alessandra Bitto 1, Gabriele Pizzino 1, Giovanni Pallio 1, Domenica Altavilla 2, Letteria Minutoli 1,*
PMCID: PMC9709692  PMID: 36467092

In the published article, the Conflict of Interest statement was incorrectly filed. The correct Conflict of Interest statement appears below.

“Author LM, FS, and AB are co-inventor on a patent describing therapeutic polydeoxyribonucleotide activity in testicular injury by torsion. Author FS has received research support from Mastelli for work on polydeoxyribonucleotide. Authors FS, AB, and DA are co-inventors on a patent describing therapeutic polydeoxyribonucleotide activity in chronic intestinal disease.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES